Bent Ejlertsen
Bent Ejlertsen
DBCG
Bekræftet mail på rh.dk
Titel
Citeret af
Citeret af
År
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 366 (9503), 2087-2106, 2005
49352005
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
26732013
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
14772015
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
6062017
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
5152013
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide …
AS Knoop, H Knudsen, E Balslev, BB Rasmussen, J Overgaard, ...
Journal of Clinical Oncology 23 (30), 7483-90, 2005
3832005
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical …
MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ...
The lancet oncology 12 (12), 1101-1108, 2011
3622011
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 …
A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ...
The Lancet Oncology 17 (3), 367-377, 2016
3602016
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ...
Jama 313 (13), 1347-1361, 2015
3082015
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The Lancet Oncology 18 (12), 1688-1700, 2017
3062017
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ...
PLoS Genet 9 (3), e1003212, 2013
2702013
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
S Møller, MB Jensen, B Ejlertsen, KD Bjerre, M Larsen, HB Hansen, ...
Acta oncologica 47 (4), 506-524, 2008
2342008
Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.
B Kristensen, B Ejlertsen, P Dalgaard, L Larsen, SN Holmegaard, ...
Journal of Clinical Oncology 12 (5), 992-997, 1994
2341994
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ...
Nature genetics 47 (2), 164-171, 2015
2222015
Oral clodronate in breast cancer patients with bone metastases: a randomized study
B Kristensen, B Ejlertsen, M Groenvold, S Hein, H Loft, HT Mouridsen
Journal of internal medicine 246 (1), 67-74, 1999
1931999
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
AD Leo, C Desmedt, J Bartlett, F Piette, B Ejlertsen, KI Pritchard, ...
The lancet oncology 12 (12), 1134-1142, 2011
1812011
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ...
Nature genetics 49 (12), 1767-1778, 2017
1662017
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ...
Nature genetics 49 (5), 680, 2017
1622017
Pregnancy after treatment of breast cancer–a population-based study on behalf of Danish Breast Cancer Cooperative Group
N Kroman, MB Jensen, J Wohlfahrt, B Ejlertsen
Acta Oncologica 47 (4), 545-549, 2008
1492008
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
PE Goss, IE Smith, J O'Shaughnessy, B Ejlertsen, M Kaufmann, F Boyle, ...
The Lancet Oncology 14 (1), 88-96, 2013
1452013
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20